[
    [
        {
            "time": "",
            "orginal_text": "江苏区域股市周报：利柏特跌出板块市值10强 158家机构调研天华超净",
            "features": {
                "keywords": [
                    "利柏特",
                    "板块市值",
                    "机构调研",
                    "天华超净"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融",
                    "制造业"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "江苏区域股市周报：利柏特跌出板块市值10强 158家机构调研天华超净",
            "scores": {
                "News_content": "江苏区域股市周报：利柏特跌出板块市值10强 158家机构调研天华超净",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "写意报告 | 中美临床试验申请的对比分析",
            "features": {
                "keywords": [
                    "中美",
                    "临床试验",
                    "对比分析"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "写意报告 | 中美临床试验申请的对比分析",
            "scores": {
                "News_content": "写意报告 | 中美临床试验申请的对比分析",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业2021年下半年投资策略：创新+消费升级 引领行业成长",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新",
                    "消费升级",
                    "投资策略"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "医药生物行业2021年下半年投资策略：创新+消费升级 引领行业成长",
            "scores": {
                "News_content": "医药生物行业2021年下半年投资策略：创新+消费升级 引领行业成长",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业2021年8月投资策略：布局业绩确定 估值合理标的",
            "features": {
                "keywords": [
                    "医药生物",
                    "业绩确定",
                    "估值合理",
                    "投资策略"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "医药生物行业2021年8月投资策略：布局业绩确定 估值合理标的",
            "scores": {
                "News_content": "医药生物行业2021年8月投资策略：布局业绩确定 估值合理标的",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "orginal_text": "芯片界“药明康德”两日涨44%，市值重回500亿，蔡嵩松二季度加仓",
            "features": {
                "keywords": [
                    "芯片",
                    "药明康德",
                    "市值",
                    "蔡嵩松",
                    "加仓"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "半导体",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "芯片界“药明康德”两日涨44%，市值重回500亿，蔡嵩松二季度加仓",
            "scores": {
                "News_content": "芯片界“药明康德”两日涨44%，市值重回500亿，蔡嵩松二季度加仓",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "又是“20cm”涨停！芯原股份近3个月股价翻倍",
            "features": {
                "keywords": [
                    "20cm",
                    "涨停",
                    "芯原股份",
                    "股价翻倍"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "半导体",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "又是“20cm”涨停！芯原股份近3个月股价翻倍",
            "scores": {
                "News_content": "又是“20cm”涨停！芯原股份近3个月股价翻倍",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "刚刚，又是“20cm”涨停！芯片界“药明康德”炸了！总市值大超寒武纪，近3个月翻倍！诺安、南方加仓，华夏、博时、易方达等新进",
            "features": {
                "keywords": [
                    "20cm",
                    "涨停",
                    "芯片",
                    "药明康德",
                    "市值",
                    "寒武纪",
                    "诺安",
                    "南方",
                    "华夏",
                    "博时",
                    "易方达"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "半导体",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "刚刚，又是“20cm”涨停！芯片界“药明康德”炸了！总市值大超寒武纪，近3个月翻倍！诺安、南方加仓，华夏、博时、易方达等新进",
            "scores": {
                "News_content": "刚刚，又是“20cm”涨停！芯片界“药明康德”炸了！总市值大超寒武纪，近3个月翻倍！诺安、南方加仓，华夏、博时、易方达等新进",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "orginal_text": "北向资金加仓A股55亿，超20亿买入这个行业，继续抛售贵州茅台（名单）",
            "features": {
                "keywords": [
                    "北向资金",
                    "加仓",
                    "A股",
                    "贵州茅台"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费",
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北向资金加仓A股55亿，超20亿买入这个行业，继续抛售贵州茅台（名单）",
            "scores": {
                "News_content": "北向资金加仓A股55亿，超20亿买入这个行业，继续抛售贵州茅台（名单）",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "58股获券商买入评级，明新旭腾目标涨幅达85.74%",
            "features": {
                "keywords": [
                    "券商",
                    "买入评级",
                    "明新旭腾",
                    "目标涨幅"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "汽车",
                    "制造业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "58股获券商买入评级，明新旭腾目标涨幅达85.74%",
            "scores": {
                "News_content": "58股获券商买入评级，明新旭腾目标涨幅达85.74%",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "北向资金动向盘点：继续重手净买“电新、电子”",
            "features": {
                "keywords": [
                    "北向资金",
                    "电新",
                    "电子",
                    "净买"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "新能源",
                    "电子"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北向资金动向盘点：继续重手净买“电新、电子”",
            "scores": {
                "News_content": "北向资金动向盘点：继续重手净买“电新、电子”",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "芯片界“药明康德”20cm涨停！盈利在望，诺安加仓",
            "features": {
                "keywords": [
                    "芯片",
                    "药明康德",
                    "20cm",
                    "涨停",
                    "盈利",
                    "诺安",
                    "加仓"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "半导体",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "芯片界“药明康德”20cm涨停！盈利在望，诺安加仓",
            "scores": {
                "News_content": "芯片界“药明康德”20cm涨停！盈利在望，诺安加仓",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "速递 | 发现慢性肾病新靶点和新化合物，AI药物发现再获积极进展",
            "features": {
                "keywords": [
                    "慢性肾病",
                    "新靶点",
                    "新化合物",
                    "AI药物发现"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物",
                    "AI"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "速递 | 发现慢性肾病新靶点和新化合物，AI药物发现再获积极进展",
            "scores": {
                "News_content": "速递 | 发现慢性肾病新靶点和新化合物，AI药物发现再获积极进展",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "速递 | 靶向DNA损伤响应机制，再鼎医药与Schrdinger合作开发抗癌疗法",
            "features": {
                "keywords": [
                    "靶向",
                    "DNA损伤",
                    "再鼎医药",
                    "Schrdinger",
                    "抗癌疗法"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "速递 | 靶向DNA损伤响应机制，再鼎医药与Schrdinger合作开发抗癌疗法",
            "scores": {
                "News_content": "速递 | 靶向DNA损伤响应机制，再鼎医药与Schrdinger合作开发抗癌疗法",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "速递 | 合作打造靶向RNA的小分子药物，灵北剑指神经系统疾病",
            "features": {
                "keywords": [
                    "靶向RNA",
                    "小分子药物",
                    "灵北",
                    "神经系统疾病"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "速递 | 合作打造靶向RNA的小分子药物，灵北剑指神经系统疾病",
            "scores": {
                "News_content": "速递 | 合作打造靶向RNA的小分子药物，灵北剑指神经系统疾病",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]